发布时间:
2020
-
08
-
15
点击次数:
0
所属职位：
首席技术官
所属公司：
EOC Pharma
个人简介：
Dr. Deepak Hegde completed his Doctorate in Biopharmaceutics and Pharmacokinetics from University of Mumbai in 1996. He also completed his Masters in Financial Management (M.F.M) from University of Mumbai in 2000. He is currently working with EOC Pharma as Chief Technology Officer. Responsible for development and manufacturing of new speciality anti cancer products for China. Prior to joining EOC, he was with GSK Shanghai, R & D China as Director, Global External Development & Supply, AsiaPacific, responsible for developing drug products for GSK global portfolio and for introduction of new products to China. Prior to this he worked with Wuxi AppTec as Vice President for Formulation Development. At WuXi Apptec, he was instrumental in setting up the Formulation Development Business as well as the formulation team, GMP facilities and systems which have since been approved by the EMA, USFDA and CFDA. While working with several multinational companies from US and Europe, he helped develop more than 150 NCE’s. He established several enabling technologies like Microdozing, Nanonization, Spray Drying, and Holt Melt Extrusion (HME) etc. at WuXi AppTec which helped customers expedite the First in Man (FIM) studies in US, Europe, Australia, Korea & China. Prior to joining WuXi AppTec in Shanghai, he has worked at several positions across Rhone Poulenc, Sandoz (A Novartis Group Company) and USV Ltd, a premier Indian Generic Company. He has extensive experience in generic formulation development of solid and liquid oral and injectible formulations from a very early phase of development all the way to technical transfers to commercial manufacturing sites. At Sandoz, he worked on formulation development for the regulated markets like US and Europe and participated in technical transfers to commercial sites of Sandoz at Rolab in South Africa, and Novartis Bangladesh and Novartis Pakistan. Several generic products that he developed have since been registered and commercially launched in Europe, USA, South Africa and Asia. He is a life member of the Indian Pharmaceutical Association. He has two US patents, five PCT and US patent applications and several National and International publications to his credit. He has extensive experience in generic formulation development of solid and liquid oral and injectible formulations from a very early phase of development all the way to technical transfers to commercial manufacturing sites. At Sandoz, he worked on formulation development for the regulated markets like US and Europe and participated in technical transfers to commercial sites of Sandoz at Rolab in South Africa, and Novartis Bangladesh and Novartis Pakistan. Several generic products that he developed have since been registered and commercially launched in Europe, USA, South Africa and Asia. He is a life member of the Indian Pharmaceutical Association. He has two US patents, five PCT and US patent applications and several National and International publications to his credit.